Phase 3 IMbrave150 Trial in Patients with Unresectable Hepatocellular Carcinoma: 2021 Update

Expert Richard Kim, MD, reflects on the nature of HCC, particularly the challenges inherent in diagnosis and management.

A comprehensive overview of the frontline treatment landscape for patients with unresectable HCC, including those who present with contraindications to standard-of-care therapy.

A brief synopsis on optimal sequencing strategies for patients who have been diagnosed with unresectable hepatocellular carcinoma.

Richard Kim, MD, shares insight on positive results from IMbrave150, which tested the frontline combination of atezolizumab and bevacizumab in patients with unresectable HCC.

Considerations for ongoing clinical trials that may shape the future treatment landscape of unresectable hepatocellular carcinoma.